Figure 4.

The treatment response and short-term outcomes of patients with autoimmune GFAP astrocytopathy. First-line immunotherapy included intravenous methylprednisolone, intravenous immunoglobulin, and plasma exchange, alone or in combination. Second-line immunotherapy included rituximab, tacrolimus, or mycophenolate mofetil. *The occurrence of improvement or absence of improvement was assessed at 4 weeks after the initiation of immunotherapy. Recovered was defined as mRS=0; mild deficits were defined as mRS= 1,2; and severe deficits were defined as mRS= 3,4.